Developing targeted inhibitors for specific forms of Casein Kinase 1 to improve cancer treatment
Official title: Computer-aided design and development of isoform selective inhibitors of Casein Kinase 1
Funded at Queens College · NIH-11081676 · Data updated 2026-11-12
This study is working on developing new treatments that specifically target certain forms of a protein called Casein Kinase 1, which is important in how cells communicate and can be involved in cancer; the goal is to create more effective cancer therapies that have fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Queens College NIH-funded |
| Lab location | 1 site (Flushing, United States) |
| Project start | May 22, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $154,000 |
| NIH project number | 5R16GM149489-03 |
| Project ID | NIH-11081676 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that are influenced by the CK1 signaling pathways.
✕Less likely to help
Patients whose cancers are not associated with CK1 signaling or those who do not respond to kinase inhibitors may not benefit from this research.
What this research studies
This research focuses on creating selective inhibitors for different isoforms of Casein Kinase 1 (CK1), which play crucial roles in cellular signaling and cancer development. By using advanced computational methods and synthetic chemistry, the project aims to address the challenge of off-target effects commonly seen with current cancer therapies. The goal is to enhance the specificity of these inhibitors, allowing for more effective treatment options with fewer side effects for patients. This work could lead to a better understanding of CK1's role in various diseases and improve therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments by providing targeted therapies that minimize side effects.
How similar studies have gone: While the development of isoform-selective inhibitors is a relatively novel approach, there have been successful instances in targeting specific kinases in cancer therapy, indicating potential for success in this area.
Where this research is happening
-
Queens College
Flushing, United States Active
Researchers
- Principal investigator: Choi, Jun-Yong — Queens College
- Study coordinator: Choi, Jun-Yong
Related research
Other NIH-funded projects on the same topics.
-
TopoROP: Multi-View Analysis to Diagnose Retinopathy of Prematurity
A new AI-based tool analyzes retinal images to help doctors diagnose Retinopathy of Prematurity in premature babies and other patients at risk.
-
Brain blood vessel changes linked to chronic nerve pain
This project looks at how changes in tiny blood vessels in the brain after nerve injury might make pain and related mood or thinking problems worse.
-
PARP-1 Degradation for Alzheimer's-related Diseases
A new approach to lower PARP-1 protein in diseased human cells to help with Alzheimer’s-related dementia and other conditions.
-
Epigenetic signals and behavioral risk after in-utero stress in children and teens
This grant investigates how a mother’s stress during pregnancy may leave epigenetic marks that influence fear, emotion regulation, and addiction risk in children as they grow up.
-
Tubulin “toggle switch” in human breast cancer
A study exploring how specific tubulin protein changes control breast cancer cell behavior, with potential implications for new treatments.
-
Understanding how early stress and brain wiring relate to anxiety and aggression in teens
This project follows kids born around Superstorm Sandy to see how early and ongoing stress affects anxiety and disruptive behavior as they grow.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.